DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis
Prospective DPYD genotyping was feasible in routine clinical practice, and DPYD genotype-based
dose reductions improved patient safety of fluoropyrimidine treatment. For DPYD*2A
and c.1679T>G carriers, a 50% initial dose reduction was adequate. For...